ClinicalTrials.gov lists 10 registered trials of Ipamorelin: 0 recruiting or about to, 0 running, 9 completed. The largest is Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function (320 people).
10registered trials
0recruiting now
0running
9completed
0in phase 3
0with results posted
Registered trials by phase. Phase 3 trials are the large ones that decide approval.
Each bar runs from a trial's start to its planned end; faded bars have no end date. Click a bar to open the trial.
Studying: Gastrointestinal Dysmotility · NCT01280344
Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.
Studying: Brain Injuries · NCT01366820
The purpose of this study is to determine whether NNZ-2566 is safe and effective in the treatment of Traumatic Brain Injury (TBI).
Studying: Brain Injuries · NCT00805818
The purpose of this study is to determine whether NNZ-2566 is safe and effective in the treatment of Traumatic Brain Injury (TBI).
Studying: Ileus · NCT00672074
The purpose of this study is to determine if ipamorelin is safe and effective in the management of post-operative ileus.
Studying: Rett Syndrome · NCT02715115
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett syndrome in children and adolescents.
Studying: Fragile X Syndrome · NCT01894958
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Fragile X Syndrome in adolescent and adult males.
Studying: Rett Syndrome · NCT01703533
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett Syndrome in adolescent and adult females.
Studying: Brain Injuries, Traumatic · NCT00961779
The purpose of this study is to obtain evidence of the safety of NNZ-2566 in healthy female volunteers and to determine the pharmacokinetics (PK) of NNZ-2566 in healthy female volunteers.
Studying: Brain Injuries, Traumatic · NCT01420042
The purpose of this study is to obtain evidence of safety and determine the pharmacokinetics (PK) of NNZ-2566 in healthy volunteers, when administered orally.
Studying: Concussion · NCT02100150
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of mTBI in adolescents and adults.
Registered trials include ones that haven't published results yet. Trials are matched on the compound's name and code names (Ipamorelin, NNZ-2566) in the listed interventions.